Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Trince logo — Precision Transfections

Trince

Precision Transfections

Founded 2014 Belgium Belgium 20 employees Unknown Total: $11.20M Biopharma, Biotechnology +1

General Information

Company Name Trince
Founded Year 2014
Location Belgium Belgium +1
Founders / Decision Makers
Team member
Employees 20
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Unknown
Social

Get notified when Trince moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Trince is strategically expanding its market presence and validating its LumiPore platform through active engagement in key industry events like the SLAS European conference, where it's nominated for an award. This visibility is coupled with robust business development efforts, evidenced by a co-hosting partnership with Aldevron and ongoing pitch-phase discussions for collaborations with major pharmaceutical corporations such as AstraZeneca and Bayer. Additionally, recent acceptance into an EIC program underscores strong institutional support and networking opportunities, collectively positioning Trince for significant commercialization breakthroughs and its upcoming Early VC funding round.

Signal Types
Market Presence Partnership Development Industry Recognition Institutional Support
Strategic Labels
Corporate Partnerships Market Expansion Technology Validation
Next Move: Fundraising
·
Impact: 9/10
·
Ideal For: Biotech VCs — Pre-Series A / Series A

About Trince

Trince, founded in 2014, is a promising biotechnology startup headquartered in Belgium. This spin-off from Ghent University is advancing the biopharma landscape with their pioneering LumiPore transfection platform, which is covered by a portfolio of pending patents.

The core innovation lies in the fusion of laser technology with photothermal nanoparticles to transiently permeabilize the cellular plasma membrane. This enables the precise delivery of a diverse range of effector molecules, including hard-to-transfect cells such as immune cells crucial for cell therapies. It elevates the efficiency of cell products for therapeutics, ensuring gentleness and quality.

Trince's commitment to precision transfections positions them within the Biopharma, Biotechnology, and Pharmaceutical industries. The company most recently secured a substantial €5.20M early VC investment in December 2025, showcasing robust confidence from investors in their innovative capacity and growth trajectory.

Taxonomy: cell-based science, therapeutics, molecule delivery, in vitro transfection, ex vivo transfection, LumiPore platform, photothermal nanoparticles, laser exposure, cell therapy, genetic material, high-throughput transfection, immune cells, cell permeabilization, hard-to-transfect cells

Services & Products

Photoporation
LumiPore Cell Transfection Platform
Research and Development Support
Cell Therapy Manufacturing

Target Customers

Biotech Researchers Clinical Researchers Pharmaceutical Companies Academic Institutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC •••••• - 01 Dec 2025
Seed •••••• 2
Investor Investor
01 Feb 2024
Spinout •••••• 2
Investor Investor
01 Dec 2021

Trince Alternatives & Competitors

View All Alternatives
Trince vs
ScienCell Research Laboratories
ScienCell Research Laboratories United States

Helping the Scientists of Today Discover the Science of Tomorrow

49 employees
Biotechnology, Clean Energy
Trince vs
Indapta Therapeutics
Indapta Therapeutics United States

A biotechnology company focused on developing a natural killer cell therapy with potent ADCC activit...

Unknown
14 employees
Biopharma, Biotechnology
Trince vs
Samplix
Samplix Denmark

Reveal cell function with single-cell resolution.

Series Unknown
35 employees
Biotechnology, Information Technology
View all alternatives

FAQ About Trince

Precision Transfections
Trince was founded in 2014.
Trince is headquartered in Belgium.
Trince operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
Trince has approximately 20 employees.
Trince has completed 3 funding rounds, raising a total of $11.20M. The latest funding stage is Unknown.
Trince offers: Photoporation, LumiPore Cell Transfection Platform, Research and Development Support, Cell Therapy Manufacturing.
Top alternatives and competitors to Trince include ScienCell Research Laboratories, Indapta Therapeutics, Samplix, Stemina Biomarker Discovery, Inc., CellFE. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Trince and ScienCell Research Laboratories are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Trince and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy